Proper nutrition support is essential not only to preserve bone and muscle and prevent micronutrient deficiencies but also to establish healthy lifestyle habits that support long-term weight management, even after discontinuing a GLP-1 medication
the medicine has not been studied in individuals under 18 years of age
In addition, GLP-1, but not GIP, inhibits glucagon secretion, and together these actions form the basis for the use of GLP-1 receptor agonists (GLP-1RAs) in T2DM therapy [6]
The project is supported by the Italian PNRR-MAD project (PNRR-MAD-2022-12375656)
In the IMPACT trial, pemvidutide achieved mean weight losses of 4.8% and 5.8% with 1.2 and 1.8 mg doses respectively at 24 weeks, compared to 0.5% with placebo, with weight loss curves showing no evidence of plateauing, suggesting continued benefit with longer treatment [49-51]